EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The CD47-SIRPα axis is a promising target for cancer immunotherapies

Yu Hao, Xinxuan Zhou, Yiling Li, Bolei Li, Lei Cheng

International Immunopharmacology · 2023-07 · 120 · 110255

DOI: 10.1016/j.intimp.2023.110255 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Yu Hao und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases & West China Hospital of Stomatology & National Clinical Research Center for Oral Diseases, Sichuan University,…. Hauptthemen laut MEDLINE: CD47 Antigen, Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 203 Literaturangaben. Gefördert von: West China School of Stomatology, Sichuan University, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cluster of differentiation 47(CD47) is a transmembrane protein that is ubiquitously found on the surface of many cells in the body and uniquely overexpressed by both solid and hematologic malignant cells. CD47 interacts with signal-regulatory protein α (SIRPα), to trigger a "don't eat me" signal and thereby achieve cancer immune escape by inhibiting macrophage-mediated phagocytosis. Thus, blocking the CD47-SIRPα phagocytosis checkpoint, for release of the innate immune system, is a current research focus. Indeed, targeting the CD47-SIRPα axis as a cancer immunotherapy has shown promising efficacies in pre-clinical outcomes. Here, we first reviewed the origin, structure, and function of the CD47-SIRPα axis. Then, we reviewed its role as a target for cancer immunotherapies, as well as the factors regulating CD47-SIRPα axis-based immunotherapies. We specifically focused on the mechanism and progress of CD47-SIRPα axis-based immunotherapies and their combination with other treatment strategies. Finally, we discussed the challenges and directions for future research and identified potential CD47-SIRPα axis-based therapies that are suitable for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenNeoplasmsHumansImmunotherapyMacrophagesPhagocytosis

Stichwörter der Autor:innen

CD47CD47-SIRPα axisImmunotherapyPhagocytosis

Substanzen

CD47 AntigenCD47 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Oral Diseases & West China Hospital of Stomatology & National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu 610041, China; Department of Operative Dentistry and Endodont…
  • State Key Laboratory of Oral Diseases & West China Hospital of Stomatology & National Clinical Research Center for Oral Diseases, Sichuan University, Chengdu 610041, China.

Förderung

  • West China School of Stomatology, Sichuan University
  • China Postdoctoral Science Foundation

Zitieren

APA

Hao, Y., Zhou, X., Li, Y., Li, B., & Cheng, L. (2023). The CD47-SIRPα axis is a promising target for cancer immunotherapies. International Immunopharmacology, 120, 110255. https://doi.org/10.1016/j.intimp.2023.110255

Vancouver

Hao Y, Zhou X, Li Y, Li B, Cheng L. The CD47-SIRPα axis is a promising target for cancer immunotherapies. International Immunopharmacology. 2023;120:110255. doi:10.1016/j.intimp.2023.110255

BibTeX
@article{Hao2023,
  author = {Hao, Yu and Zhou, Xinxuan and Li, Yiling and Li, Bolei and Cheng, Lei},
  title = {The CD47-SIRPα axis is a promising target for cancer immunotherapies},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {120},
  pages = {110255},
  doi = {10.1016/j.intimp.2023.110255}
}
Kostenlos starten →